Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Hemodynamic Instability Prevented With Polaramine® Infusion Before Extracorporeal Circulation
NCT02675374 · University Hospital, Bordeaux · PHASE3 · terminated · last registry update 2026-06-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “stop due to medication error with the placebo” | – | Registry record, University Hospital, Bordeaux |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HRH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-25Results posted on the registry: Harmony Biosciences Management, Inc., Open-label Pitolisant + Double-blind Placebo (NCT05156047)
- 2026-09-04Also stopped (withdrawn): University of Cincinnati, Antihistamine + Placebo (NCT04612803)
- 2026-08-04Also stopped (terminated): Genzyme, a Sanofi Company, Alemtuzumab GZ402673 + Glatiramer acetate (NCT03368664)
- 2026-07-24Results posted on the registry: Hoffmann-La Roche, Ocrelizumab + Ocrelizumab (NCT04548999)
- 2026-06-04Phase 3 first posted: Brainfarma Industria Química e Farmacêutica S/A, dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg + dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg (NCT07626437)
- 2026-05-18Results posted on the registry: University of Alabama at Birmingham, Psilocybin + Diphenhydramine (NCT02037126)
- 2026-03-18Also stopped (terminated): Centre Oscar Lambret, pursuit of chemotherapy (NCT03301454)
- 2026-02-27Phase 3 first posted: Shi Tianming, Rimegepant 75mg Orally Disintegrating Tablets (ODT) + Betahistine Mesylate tablet (NCT07435090)
- 2026-02-17Results posted on the registry: Hoffmann-La Roche, Ocrelizumab + Ocrelizumab (NCT04544436)
- 2026-02-05Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), elotuzumab + placebo for elotuzumab (NCT04918147)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 + Placebo (NCT02065336)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 Injection + entecavir (NCT02738008)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 + entecavir (NCT02604212)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 + entecavir (NCT02577029)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 Injection + entecavir (NCT02604199)
- 2026-01-12Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-521 Injection + antihistamine (NCT02797522)
- 2025-08-11Phase 3 first posted: Md. Hazrat Ali, ebastine + Placebo (NCT07114055)
- 2025-07-17Results posted on the registry: Emory University, Cetirizine + Famotidine (NCT05946551)
- 2025-07-17Also stopped (terminated): Emory University, Cetirizine + Famotidine (NCT05946551)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision